Posted by Michael Wonder on 24 May 2023
Sarepta Therapeutics announces update on regulatory review of SRP-9001
24 May 2023 - New regulatory action date is 22 June 2023.
Sarepta Therapeutics today provided the following update on the biologics license application for SRP-9001 (delandistrogene moxeparvovec), which is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy who have a confirmed mutation of the Duchenne muscular dystrophy gene.
